Assessing COVID-19 antibody responses in people with cystic fibrosis
COVID-19 Antibody Responses In Cystic Fibrosis: CAR-CF
Centro Hospitalar Universitário Lisboa Norte · NCT06274840
This study is trying to see how people with cystic fibrosis respond to COVID-19 by checking their antibody levels over two years to understand any effects on their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Centro Hospitalar Universitário Lisboa Norte (other) |
| Locations | 1 site (Lisbon) |
| Trial ID | NCT06274840 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the presence of SARS-CoV-2 antibodies in individuals with cystic fibrosis (pwCF) over a two-year period. It will involve repeated blood sampling at various intervals to monitor antibody levels and assess any clinical implications related to COVID-19 in pwCF. Participants will be recruited from pediatric and adult cystic fibrosis centers across Europe, and their clinical data will be collected alongside routine care visits. The study seeks to understand whether pwCF have unique immune responses to COVID-19 and how this affects their cystic fibrosis condition.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals of any age with a confirmed diagnosis of cystic fibrosis who can provide informed consent.
Not a fit: Patients who refuse to give informed consent or have contraindications to venepuncture will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the immune response of pwCF to COVID-19, potentially leading to improved care strategies for this vulnerable population.
How similar studies have performed: Other studies have explored immune responses to COVID-19 in various populations, but this specific focus on cystic fibrosis is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Consenting people with cystic fibrosis of any age, genotype, transplant status and disease severity Exclusion Criteria: * Refusal to give informed consent * Contraindication to venepuncture
Where this trial is running
Lisbon
- CHLN — Lisbon, Portugal (RECRUITING)
Study contacts
- Study coordinator: Celeste Barreto, MD
- Email: celeste.barreto@chln.min-saude.pt
- Phone: 00351210405814
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: COVID-19, Cystic Fibrosis